Insmed (NASDAQ: INSM) reported Q1 EPS of ($1.17), $0.04 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.93 million.

GUIDANCE:

Insmed sees FY2023 revenue of $285-300 million, versus the consensus of $293 million.

For earnings history and earnings-related data on Insmed (INSM) click here.